Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages 625-644

  Bougen, Nicola M ^a,c   Steiner, Michael ^a   Pertziger, Mikhail ^a   Banerjee, Arindam ^a   Brunet Dunand, Severine E ^a   Zhu, Tao ^b   Lobie, Peter E ^a,c   Perry, Jo K ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; JANUS KINASE 2; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CELL COUNT; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENDOMETRIUM CARCINOMA; IN VITRO STUDY; IONIZING RADIATION; RADIOSENSITIVITY;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN GROWTH HORMONE; HUMANS; MICE; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-PROTECTIVE AGENTS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867406801     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0042     Document Type: Article

References (88)

1. Alexandrides T, Spiliotis J, Mylonas P, Melachrinou M, Kardamakis D, Spiliopoulou I, Panagopoulos C & Kalfarentzos F 1998 Effects of growth hormone and insulin-like growth factor-I on radiation enteritis: a comparative study. European Surgical Research 30 305-311. (doi:10.1159/000008592)
2. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK et al. 2009 Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 150 4473-4483. (doi:10.1210/en.2009-0066)
3. Ayalon D, Peyser MR, Limor R, Lessing JB & Ravid R 1982 Paradoxical hypersecretion of growth hormone in patients with endometrial atypical hyperplasia and carcinoma. Effect of hysterectomy. Gynecologic and Obstetric Investigation 13 9-16. (doi:10.1159/000299479)
4. Ayouaz A, Raynaud C, Heride C, Revaud D & Sabatier L 2008 Telomeres: hallmarks of radiosensitivity. Biochimie 90 60-72. (doi:10.1016/j.biochi.2007. 09.011)
5. Begg AC, Stewart FA & Vens C 2011 Strategies to improve radiotherapy with targeted drugs. Nature Reviews. Cancer 11 239-253. (doi:10.1038/nrc3007)
6. Blasco MA 2003 Mammalian telomeres and telomerase: why they matter for cancer and aging. European Journal of Cell Biology 82 441-446. (doi:10.1078/0171-9335-00335)
7. Bougen NM, Yang T, Chen H, Lobie PE & Perry JK 2011 Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. Oncology Reports 26 487-493.
8. Branzei D & Foiani M 2008 Regulation of DNA repair throughout the cell cycle. Nature Reviews. Molecular Cell Biology 9 297-308. (doi:10.1038/nrm2351)
9. Brooks AJ & Waters MJ 2010 The growth hormone receptor: mechanism of activation and clinical implications. Nature Reviews. Endocrinology 6 515-525. (doi:10.1038/nrendo.2010.123)
10. Brown JM & Attardi LD 2005 The role of apoptosis in cancer development and treatment response. Nature Reviews. Cancer 5 231-237. (doi:10.1038/nrc1560)
11. Brown ET, Robinson-Benion C & Holt JT 2008 Radiation enhances caspase 3 cleavage of Rad51 in BRCA2-defective cells. Radiation Research 169 595-601. (doi:10.1667/RR1129.1)
12. Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, Print C, Mertani HC, Lobie PE & Perry JK 2009 Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150 1341-1352. (doi:10.1210/en.2008-0608)
13. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA, Reina-San-Martin B, Coppola V, Meffre E, Difilippantonio MJ et al. 2002 Genomic instability in mice lacking histone H2AX. Science 296 922-927. (doi:10.1126/science.1069398)
14. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, Owzar K, Wang X, Gesty-Palmer D, Cline JM, Bourland JD et al. 2010 Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. PLoS ONE 5 e11056. (doi:10.1371/journal.pone.0011056)
15. Chiarenza A, Lempereur L, Palmucci T, Cantarella G, Amico-Roxas M, Goffin V, Murabito P, Magro G & Bernardini R 2000 Responsiveness of irradiated rat anterior pituitary cells to hypothalamic releasing hormones is restored by treatment with growth hormone. Neuroendocrinology 72 392-399. (doi:10.1159/000054608)
16. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH & Margison GP 2001 Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Research 29 1534-1538. (doi:10.1093/nar/29.7.1534)
17. Daboussi F, Dumay A, Delacote F & Lopez BS 2002 DNA double-strand break repair signalling: the case of RAD51 post-translational regulation. Cell Signalling 14 969-975. (doi:10.1016/S0898-6568(02)00052-9)
18. Dumont F, Altmeyer A & Bischoff P 2009 Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opinion on Therapeutic Patents 19 775-799. (doi:10.1517/13543770902967666)
19. Dutreix M, Cosset J & Sun JS 2010 Molecular therapy in support to radiotherapy. Mutation Research 704 182-189. (doi:10.1016/j.mrrev.2010.01.001)
20. Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ & Huang TT 2005 CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 24 367-380. (doi:10.1038/sj.onc.1208207)
21. Emerald BS, Chen Y, Zhu T, Zhu Z, Lee KO, Gluckman PD & Lobie PE 2007 AlphaCP1 mediates stabilization of hTERT mRNA by autocrine human growth hormone. Journal of Biological Chemistry 282 680-690. (doi:10.1074/jbc. M600224200)
22. Eriksson D & Stigbrand T 2010 Radiation-induced cell death mechanisms. Tumour Biology 31 363-372. (doi:10.1007/s13277-010-0042-8)
23. Estrela JM, Ortega A & Obrador E 2006 Glutathione in cancer biology and therapy. Critical Reviews in Clinical Laboratory Sciences 43 143-181. (doi:10.1080/10408360500523878)
24. Gallagher EJ & Leroith D 2011 Is growth hormone resistance/IGF-1 reduction good for you? Cell Metabolism 13 355-356. (doi:10.1016/j.cmet.2011.03. 003)
25. Gomez-de-Segura IA, Prieto I, Grande AG, Garcia P, Guerra A, Mendez J & De Miguel E 1998 Growth hormone reduces mortality and bacterial translocation in irradiated rats. Acta Oncologica 37 179-185. (doi:10.1080/028418698429748)
26. Gray LH, Conger AD, Ebert M, Hornsey S & Scott OC 1953 The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology 26 638-648. (doi:10.1259/0007-1285-26-312-638)
27. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S et al. 2011 Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine 3 70ra13. (doi:10.1126/scitranslmed.3001845)
28. Harvey S 2010 Extrapituitary growth hormone. Endocrine 38 335-359. (doi:10.1007/s12020-010-9403-8)
29. Huang Y, Nakada S, Ishiko T, Utsugisawa T, Datta R, Kharbanda S, Yoshida K, Talanian RV, Weichselbaum R, Kufe D et al. 1999 Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Molecular and Cellular Biology 19 2986-2997.
30. Isla A, Budke M, Cacicedo L, Garcia-Grande A, Vazquez-Rodriguez I, De Miguel E & Perez-Alvarez M 2002 Protective effects of growth hormone en cell cultures of the central nervous system. Revista de Neurología 34 208-211.
31. Isla A, Budke M, Garcia-Grande A, Gomez de la Riva A, Morales C & Rey J 2007 Protective effects of the growth hormone (GH) on the irradiated spinal cord in rats. Neurocirugía 18 89-94.
32. Jameel JKA, Rao VSR, Cawkwell L & Drew PJ 2004 Radioresistance in carcinoma of the breast. Breast 13 452-460. (doi:10.1016/j.breast.2004.08.004)
33. Jeggo P & Lobrich M 2006 Radiation-induced DNA damage responses. Radiation Protection Dosimetry 122 124-127. (doi:10.1093/rpd/ncl495)
34. Karar J & Maity A 2009 Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biology & Therapy 8 1994-2001. (doi:10.4161/cbt.8.21.9988)
35. Kaulsay KK, Zhu T, Bennett W, Lee KO & Lobie PE 2001 The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142 767-777. (doi:10.1210/en.142.2.767)
36. Kleinberg DL, Wood TL, Furth PA & Lee AV 2009 Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocrine Reviews 30 51-74. (doi:10.1210/er.2008-0022)
37. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 23 623-646. (doi:10.1210/er.2001-0022)
38. van der Lely AJ & Kopchick JJ 2006 Growth hormone receptor antagonists. Neuroendocrinology 83 264-268. (doi:10.1159/000095537)
39. Lempereur L, Brambilla D, Scoto GM, D'Alcamo M, Goffin V, Crosta L, Palmucci T, Rampello L, Bernardini R & Cantarella G 2003 Growth hormone protects human lymphocytes from irradiation-induced cell death. British Journal of Pharmacology 138 1411-1416. (doi:10.1038/sj.bjp.0705173)
40. Le Scodan R, Cizeron-Clairac G, Fourme E, Meseure D, Vacher S, Spyratos F, de la Lande B, Cvitkovic F, Lidereau R & Bieche I 2010 DNA repair gene expression and risk of locoregional relapse in breast cancer patients. International Journal of Radiation Oncology, Biology, Physics 78 328-336. (doi:10.1016/j.ijrobp.2009.07.1735)
41. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L & Fan Z 2003 Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Molecular Cancer Therapeutics 2 353-360.
42. Ling L, Zhu T & Lobie PE 2003 Src-CrkII-C3G-dependent activation of Rap1 switches growth hormone-stimulated p44/42 MAP kinase and JNK/SAPK activities. Journal of Biological Chemistry 278 27301-27311. (doi:10.1074/jbc.M302516200)
43. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG & Langenhuijsen MM 1994 A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. Journal of Immunological Methods 174 311-320. (doi:10.1016/0022-1759(94)90034-5)
44. LoPiccolo J, Granville CA, Gills JJ & Dennis PA 2007 Targeting Akt in cancer therapy. Anti-Cancer Drugs 18 861-874.
45. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H & Sturzbecher HW 2000a DNA repair and recombination factor Rad51 is overexpressed in human pancreatic adenocarcinoma. Oncogene 19 2791-2795. (doi:10.1038/sj.onc.1203578)
46. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, Feller AC, Lopens A, Diedrich K, Schwinger E et al. 2000b Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. International Journal of Cancer 88 907-913. (doi:10.1002/1097-0215(20001215)88:6 〈907::AID-IJC11〉 3.0.CO;2-4)
47. MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H & Olive PL 2003 Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. International Journal of Radiation Biology 79 351-358. (doi:10.1080/0955300032000093128)
48. Madrid O, Varea S, Sanchez-Perez I, Gomez-Garcia L, De Miguel E, Gomez De Segura IA & Perona R 2002 Growth hormone protects against radiotherapy-induced cell death. European Journal of Endocrinology 147 535-541. (doi:10.1530/eje.0.1470535)
49. Mathioudakis N & Salvatori R 2008 Adult-onset growth hormone deficiency: causes, complications and treatment options. Current Opinion in Endocrinology, Diabetes and Obesity 15 352-358.
50. Mertani HC, Zhu T, Goh EL, Lee KO, Morel G & Lobie PE 2001 Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression. Identification of CHOP as a mediator of hGH-stimulated human mammary carcinoma cell survival. Journal of Biological Chemistry 276 21464-21475. (doi:10.1074/jbc.M100437200)
51. Morante J, Vallejo-Cremades MT, Gomez-Garcia L, Vazquez I, Gomez-de-Segura IA, Sanchez M & De Miguel E 2003 Differential action of growth hormone in irradiated tumoral and nontumoral intestinal tissue. Digestive Diseases and Sciences 48 2159-2166. (doi:10.1023/B:DDAS.0000004520.71462.c9)
52. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD & Lobie PE 2004 Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. PNAS 101 15166-15171. (doi:10.1073/pnas.0405881101)
53. Mylonas PG, Matsouka PT, Papandoniou EV, Vagianos C, Kalfarentzos F & Alexandrides TK 2000 Growth hormone and insulin-like growth factor I protect intestinal cells from radiation induced apoptosis. Molecular and Cellular Endocrinology 160 115-122. (doi:10.1016/S0303-7207(99)00215-4)
54. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J et al. 2005 Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology 77 18-24. (doi:10.1016/j.radonc. 2005.06.038)
55. Ohnishi T, Taki T, Hiraga S, Arita N & Morita T 1998 In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochemical and Biophysical Research Communications 245 319-324. (doi:10.1006/bbrc.1998.8440)
56. Olive PL & Banath JP 2006 The comet assay: a method to measure DNA damage in individual cells. Nature Protocols 1 23-29. (doi:10.1038/nprot.2006.5)
57. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T & Lobie PE 2008 Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149 3909-3919. (doi:10.1210/en.2008-0286)
58. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M & Bonner WM 2000 A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Current Biology 10 886-895. (doi:10.1016/S0960- 9822(00)00610-2)
59. Perry JK, Emerald BS, Mertani HC & Lobie PE 2006 The oncogenic potential of growth hormone. Growth Hormone & IGF Research 16 277-289. (doi:10.1016/j.ghir.2006.09.006)
60. Perry JK, Mohankumar KM, Emerald BS, Mertani HC & Lobie PE 2008 The contribution of growth hormone to mammary neoplasia. Journal of Mammary Gland Biology & Neoplasia 13 131-145. (doi:10.1007/s10911-008-9070-z)
61. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S & Stuerzbecher HW 2005 High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. British Journal of Cancer 93 137-143. (doi:10.1038/sj.bjc.6602665)
62. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S & Haaf T 2002 Elevated levels of Rad51 recombination protein in tumor cells. Cancer Research 62 219-225.
63. Raguso CA, Leverve X & Pichard C 2002 Protective effects of recombinant growth hormone on intestinal mucosa in rats receiving abdominal radiotherapy. Clinical Nutrition 21 487-490. (doi:10.1054/clnu.2002.0579)
64. Richardson C 2005 RAD51, genomic stability, and tumorigenesis. Cancer Letters 218 127-139. (doi:10.1016/j.canlet.2004.08.009)
65. Rogakou EP, Pilch DR, Orr AH, Ivanova VS & Bonner WM 1998 DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. Journal of Biological Chemistry 273 5858-5868. (doi:10.1074/jbc.273.10.5858)
66. Rubio MA, Davalos AR & Campisi J 2004 Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress. Experimental Cell Research 298 17-27. (doi:10.1016/j.yexcr.2004.04.004)
67. Russo AL, Citrin D & Camphausen K 2008 Biomarkers in radiation oncology. Biomarkers in Medicine 2 155-163. (doi:10.2217/17520363.2.2.155)
68. Sharda N, Yang C-R, Kinsella T & Boothman D 2002 Radiation resistance. In Encyclopedia of Cancer. San Diego, CA, USA: Academic Press.
69. Shevah O & Laron Z 2007 Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Hormone & IGF Research 17 54-57. (doi:10.1016/j.ghir.2006.10.007)
70. Shinohara ET & Maity A 2009 Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Current Molecular Medicine 9 1034-1045. (doi:10.2174/ 156652409789839107)
71. Slater M, Cooper M & Murphy CR 2006 Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochemica 108 13-18. (doi:10.1016/j.acthis.2006.01.004)
72. Southgate TD, Sheard V, Milsom MD, Ward TH, Mairs RJ, Boyd M & Fairbairn LJ 2006 Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase. Journal of Gene Medicine 8 557-565. (doi:10.1002/jgm.890)
73. Steuerman R, Shevah O & Laron Z 2011 Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. European Journal of Endocrinology 164 485-489. (doi:10.1530/EJE-10-0859)
74. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M & Jeggo PA 2004 ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Research 64 2390-2396. (doi:10.1158/0008-5472.CAN-03- 3207)
75. Tanaka T, Kurose A, Huang X, Traganos F, Dai W & Darzynkiewicz Z 2006 Extent of constitutive histone H2AX phosphorylation on Ser-139 varies in cells with different TP53 status. Cell Proliferation 39 313-323. (doi:10.1111/j.1365- 2184.2006.00387.x)
76. Tekin SB, Ertekin MV, Erdogan F, Sezen O, Karslioglu I, Gepdiremen A, Serifoglu K & Altas S 2006 Is growth hormone a radioprotective agent? Journal of the European Academy of Dermatology and Venereology 20 293-298. (doi:10.1111/j.1468-3083.2006.01454.x)
77. Tennant AH & Kligerman AD 2011 Superoxide dismutase protects cells from DNA damage induced by trivalent methylated arsenicals. Environmental and Molecular Mutagenesis 52 238-243. (doi:10.1002/em.20609)
78. Vazquez I, Gomez-de-Segura IA, Grande AG, Escribano A, Gonzalez-Gancedo P, Gomez A, Diez R & De Miguel E 1999 Protective effect of enriched diet plus growth hormone administration on radiation-induced intestinal injury and on its evolutionary pattern in the rat. Digestive Diseases and Sciences 44 2350-2358. (doi:10.1023/A:1026637611298)
79. Wu X, Wan M, Li G, Xu Z, Chen C, Liu F & Li J 2006 Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy. European Journal of Cancer 42 888-894. (doi:10.1016/j.ejca.2005. 12.012)
80. Wu ZS, Yang K, Wan Y, Qian PX, Perry JK, Chiesa J, Mertani HC, Zhu T & Lobie PE 2011 Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. Journal of Clinical Endocrinology and Metabolism 96 E1619-E1629. (doi:10.1210/jc.2011-1245)
81. Xia SJ, Shammas MA & Shmookler Reis RJ 1997 Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Molecular and Cellular Biology 17 7151-7158.
82. Xu XQ, Emerald BS, Goh ELK, Kannan N, Miller LD, Gluckman PD, Liu ET & Lobie PE 2005 Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. Journal of Biological Chemistry 280 23987-24003. (doi:10.1074/jbc.M503869200)
83. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ & Hamilton TC 1995 Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Research 55 4367-4374.
84. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA & Sharma A 2007 Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clinical Cancer Research 13 1000-1009. (doi:10.1158/1078-0432.CCR-06-1910)
85. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E et al. 2007 Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecologic Oncology 107 58-65. (doi:10.1016/j.ygyno.2007. 05.041)
86. Zaidi SH, Huddart RA & Harrington KJ 2009 Novel targeted radiosensitisers in cancer treatment. Current Drug Discovery Technologies 6 103-134. (doi:10.2174/157016309788488348)
87. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC & Lobie PE 2005a Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Research 65 317-324.
88. Zhu Z, Mukhina S, Zhu T, Mertani HC, Lee K-O & Lobie PE 2005b p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 24 3774-3785. (doi:10.1038/sj.onc.1208541)